Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| SLNO | EFFECT | bearish | 5/10 | Soleno Therapeutics' shelf registration statement on Form S-3 (File No. 333-275120) was declared effective by the SEC on | May 28, 2026 |
| AIMD | CLUSTER | neutral | 2/10 | Ainos, Inc. (AIMD) insiders executed a mixed cluster of trades over a 7-day window ending May 22, 2026. Two directors so | May 27, 2026 |
| HCWB | CLUSTER | bullish | 6/10 | Two HCWB insiders (Director Garrett and CFO Byam) made open-market purchases totaling $270K on May 22, 2026, at $1.405/s | May 27, 2026 |
| VSTM | 3 | neutral | 2/10 | Michael P. Bailey filed a Form 3 initial statement of beneficial ownership upon becoming a director of Verastem, Inc. Th | May 27, 2026 |
| HOTH | 424B5 | bearish | 6/10 | Rocket One Inc. (RKTO) filed a 424B5 prospectus supplement to increase its at-the-market (ATM) offering by up to $2.66 m | May 27, 2026 |
| XLO | S-3/A | neutral | 4/10 | Xilio Therapeutics filed Amendment No. 1 to its S-3 shelf registration, registering up to $250M in securities (common, p | May 27, 2026 |
| ONC | CLUSTER | neutral | 2/10 | Two directors at BeOne Medicines sold a combined $131K in open-market transactions on May 22, 2026. The total value repr | May 27, 2026 |
| BHVN | 8-K | bullish | 7/10 | Biohaven reported multiple positive pipeline updates at its May 2026 R&D Day, including: 1) Opakalim (Kv7 activator) sho | May 27, 2026 |
| PCRX | DEFA14A | mixed | 5/10 | Pacira BioSciences issued a DEFA14A letter to stockholders ahead of its June 9, 2026 Annual Meeting, urging support for | May 27, 2026 |
| DRMAW | 8-K | neutral | 3/10 | Dermata Therapeutics held its 2026 Annual Meeting on May 27, 2026. Stockholders approved several proposals including the | May 27, 2026 |
| SLNCF | 424B5 | bearish | 6/10 | Silence Therapeutics filed a prospectus supplement to activate an at-the-market (ATM) offering of up to $100M in ADSs th | May 27, 2026 |
| VSTM | 144 | neutral | 3/10 | Director Robert Gagnon filed a Form 144 to sell 20,103 shares of Verastem common stock, with an estimated aggregate mark | May 27, 2026 |
| ANAB | 144 | bearish | 6/10 | CEO Dennis Mulroy filed a Form 144 notice to sell 10,000 shares of AnaptysBio common stock, valued at approximately $585 | May 27, 2026 |
| MDCXW | 8-K | bearish | 8/10 | Medicus Pharma entered into a $22M secured note financing with Streeterville Capital, with $12M received upfront and $10 | May 27, 2026 |
| ICLR | 6-K | bearish | 8/10 | ICON plc filed Q4/FY2025 results alongside the conclusion of an Audit Committee investigation that found revenue oversta | May 27, 2026 |
| ARTL | 8-K | bearish | 6/10 | Artelo Biosciences entered into a new $6.5M at-the-market (ATM) equity offering agreement with H.C. Wainwright, replacin | May 27, 2026 |
| TGTX | 8-K | bullish | 7/10 | TG Therapeutics announced positive topline results from the Phase 3 ENHANCE trial, which met its primary endpoint by dem | May 27, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt made a $864K open-market purchase of 1,500 shares at $575.96 on 2026-05-26, alongside derivative e | May 27, 2026 |
| COCP | DEFA14A | neutral | 2/10 | Cocrystal Pharma filed a DEFA14A notice providing the logistics for its 2026 Annual Meeting of Stockholders to be held v | May 27, 2026 |
| MEHA | DEFA14A | mixed | 5/10 | Functional Brands Inc. issued an urgent DEFA14A reminder about its Special Meeting on May 28, 2026, with a vote cut-off | May 27, 2026 |
| ICLR | 20-F | bearish | 8/10 | ICON plc filed its FY2025 20-F, which restates FY2023 and FY2024 financials due to an Audit Committee investigation that | May 27, 2026 |
| RDHL | 6-K | bearish | 6/10 | RedHill Biopharma filed a 6-K on May 27, 2026, to report a May 7, 2026 prospectus supplement that increases the maximum | May 27, 2026 |
| OTLK | CLUSTER | bullish | 5/10 | Two directors at Outlook Therapeutics made open-market purchases totaling ~$179K on May 26, 2026, just 13 days after the | May 27, 2026 |
| MEHA | DEFA14A | mixed | 6/10 | Functional Brands management issued a DEFA14A reminder letter to shareholders urging them to vote before the May 27 cut- | May 27, 2026 |
| INCY | DEFA14A | neutral | 3/10 | Incyte filed additional proxy soliciting materials supplementing its definitive proxy statement for the June 8, 2026 ann | May 27, 2026 |
| GLAXF | 6-K | neutral | 1/10 | GSK plc filed a Form 6-K reporting an acquisition of 9.293 American Depositary Shares by Maya Martinez-Davis, President | May 27, 2026 |
| SNYNF | 6-K | bullish | 5/10 | Sanofi announced positive Phase 2 data for efdoralprin alfa in alpha-1 antitrypsin deficiency (AATD), showing statistica | May 27, 2026 |
| HYFT | 6-K | neutral | 4/10 | MindWalk Holdings launched its Pandemic Response Platform, a deployable configuration of its HYFT/LensAI system for rapi | May 27, 2026 |
| RAPP | 144 | bearish | 5/10 | Third Rock Ventures V, L.P., a 10% stockholder, filed a Form 144 on May 27, 2026, indicating intent to sell 18,572 share | May 27, 2026 |
| JAGX | 8-K | neutral | 4/10 | Jaguar Health received formal notice from Nasdaq on May 26, 2026 that it has regained compliance with the $1.00 bid pric | May 27, 2026 |